Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
LIV007 is a natural live biotherapeutic product (nLBP) being developed by Liveome for the treatment of atopic dermatitis. As an nLBP, it consists of naturally occurring bacterial strains selected for their therapeutic potential, distinguishing it from engineered live biotherapeutic products (eLBPs). The drug is designed to address the microbial dysbiosis and inflammatory processes associated with atopic dermatitis, a chronic skin condition. Currently in the preclinical stage, LIV007 aims to provide a microbiome-based approach to restoring skin health and immune balance by utilizing the therapeutic properties of specific, non-modified bacterial strains.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on LIV007.